ValuEngine Lowers Recro Pharma (REPH) to Hold

Share on StockTwits

Recro Pharma (NASDAQ:REPH) was downgraded by stock analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Monday, ValuEngine reports.

A number of other analysts have also recently commented on the stock. Zacks Investment Research upgraded shares of Recro Pharma from a “hold” rating to a “buy” rating and set a $9.25 target price on the stock in a report on Wednesday, April 24th. Oppenheimer boosted their target price on shares of Recro Pharma from $9.00 to $15.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Roth Capital restated a “neutral” rating and set a $7.50 target price (down previously from $15.00) on shares of Recro Pharma in a report on Monday, March 25th. Finally, Janney Montgomery Scott restated a “buy” rating and set a $13.00 target price on shares of Recro Pharma in a report on Thursday, January 31st. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. Recro Pharma presently has a consensus rating of “Buy” and a consensus target price of $10.95.

Shares of REPH stock traded down $0.20 during mid-day trading on Monday, reaching $8.90. 433,100 shares of the company’s stock traded hands, compared to its average volume of 368,263. Recro Pharma has a 12 month low of $4.78 and a 12 month high of $13.05. The stock has a market cap of $193.52 million, a PE ratio of -3.57 and a beta of -0.13. The company has a current ratio of 2.45, a quick ratio of 2.08 and a debt-to-equity ratio of 4.04.

Recro Pharma (NASDAQ:REPH) last announced its earnings results on Friday, May 10th. The specialty pharmaceutical company reported ($0.10) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.79) by $0.69. Recro Pharma had a negative net margin of 103.07% and a negative return on equity of 472.58%. The firm had revenue of $25.07 million for the quarter, compared to analysts’ expectations of $20.51 million. On average, sell-side analysts forecast that Recro Pharma will post -1.94 earnings per share for the current fiscal year.

A number of institutional investors have recently made changes to their positions in REPH. Renaissance Technologies LLC boosted its stake in Recro Pharma by 26.0% in the 3rd quarter. Renaissance Technologies LLC now owns 480,500 shares of the specialty pharmaceutical company’s stock worth $3,416,000 after purchasing an additional 99,200 shares in the last quarter. Oppenheimer & Co. Inc. boosted its stake in Recro Pharma by 5.5% in the 4th quarter. Oppenheimer & Co. Inc. now owns 32,313 shares of the specialty pharmaceutical company’s stock worth $229,000 after purchasing an additional 1,683 shares in the last quarter. Rhumbline Advisers boosted its stake in Recro Pharma by 47.8% in the 4th quarter. Rhumbline Advisers now owns 23,753 shares of the specialty pharmaceutical company’s stock worth $169,000 after purchasing an additional 7,679 shares in the last quarter. Essex Investment Management Co. LLC boosted its stake in Recro Pharma by 1.9% in the 4th quarter. Essex Investment Management Co. LLC now owns 257,707 shares of the specialty pharmaceutical company’s stock worth $1,830,000 after purchasing an additional 4,833 shares in the last quarter. Finally, Monarch Partners Asset Management LLC boosted its stake in Recro Pharma by 57.4% in the 4th quarter. Monarch Partners Asset Management LLC now owns 55,857 shares of the specialty pharmaceutical company’s stock worth $397,000 after purchasing an additional 20,367 shares in the last quarter. Institutional investors own 55.42% of the company’s stock.

Recro Pharma Company Profile

Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.

Read More: Trading Ex-Dividend Strategy

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Golar LNG Partners  Scheduled to Post Earnings on Tuesday
Golar LNG Partners Scheduled to Post Earnings on Tuesday
Research Analysts Issue Forecasts for Nephros, Inc.’s Q2 2019 Earnings
Research Analysts Issue Forecasts for Nephros, Inc.’s Q2 2019 Earnings
Consolidated Edison  Hits New 12-Month High on Analyst Upgrade
Consolidated Edison Hits New 12-Month High on Analyst Upgrade
ValuEngine Downgrades Just Energy Group  to Strong Sell
ValuEngine Downgrades Just Energy Group to Strong Sell
PBF Energy Inc  to Post Q2 2019 Earnings of $0.95 Per Share, Piper Jaffray Companies Forecasts
PBF Energy Inc to Post Q2 2019 Earnings of $0.95 Per Share, Piper Jaffray Companies Forecasts
Head to Head Contrast: Equinix  versus Saul Centers
Head to Head Contrast: Equinix versus Saul Centers


© 2006-2019 Ticker Report